tiprankstipranks
Mizuho doubts BridgeBio selling itself, says royalty deal more likely
The Fly

Mizuho doubts BridgeBio selling itself, says royalty deal more likely

Mizuho says there is a lot of investor discussion of BridgeBio getting potentially taken out after its cancellation from a Guggenheim conference next week. The analyst, however, does not believe BridgeBio will sell itself. What is more likely than a sale is a royalty deal, the analyst tells investors in a research note. The firm believes a royalty deal will allow the company to "strategically maintain upside" on acoramidis while extending its cash runway just in case the acoramidis Phase 3 trial fails. Syed keeps a Buy rating on BridgeBio with a $23 price target.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on BBIO:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles